What are the Challenges faced by the Therapeutic Market of Hematological Malignancies Disease?
The pharmaceutical industry’s growing interest in the treatment potential of hematological malignancies has accelerated the market’s growth.
According to BIS Research, the global hematological malignancies emerging therapeutics industry analysis by BIS Research projects the market to grow at a significant CAGR of 14.20% during the forecast period 2021–2031.
Although monoclonal antibodies are used in the commercialized products for the treatment of hematological malignancies, the use of chimeric antigen receptor (CAR) T-cell therapy is expected to grow due to its ability to address unmet medical needs and overcome limitations associated with monoclonal antibodies.
Hematological malignancy therapies based on monoclonal antibodies (mAB) are a form of targeted therapy that is particularly designed to interact with a specific biomarker. Some mAB-based therapies are called “immunotherapies” since they impact a patient’s immune system to fight malignancy.
Chimeric antigen receptor (CAR) T-cell therapy is used to treat hematological malignancies that use immune system T-cells that have been genetically modified to combat cancer. When CAR-T cells are injected into a patient’s body, the receptors let the cells connect to particular antigens on the tumor, causing the cancer cell to die.
The recent growth in the number of therapeutic approvals for various forms of hematological malignancies is seen to be of additional value in the growing prospective drug development.
Challenges Impacting therapeutical Industry
High adoption costs: Emerging targeted medicines, like monoclonal antibodies and CAR-T-based cell therapies, have acquired significant momentum in the oncology community and regulatory authorities in recent years for the treatment of several hematological malignancy subtypes.
While targeted treatments in the field of hematological malignancies have become an essential component of providing a value-based treatment, the expense of these medicines makes them difficult for patients to pay.
The high cost of these targeted medications for the treatment of advanced hematological malignancies is the primary barrier to access the drugs.
As a result, unless appropriate payment models are implemented, the high cost of monoclonal antibody and CAR-T-based cell treatments will offer a significant hurdle to the hematological malignancies emerging therapeutics market, limiting its expansion.
Reimbursement: Cancer medications, especially hematological malignancy treatments, have typically faced few constraints since cancer patients begin and continue to receive low-cost chemotherapies.
However, new medicines are developed and released, funding for these drugs is getting more difficult. Out-of-pocket expenses for innovative cancer medications, such as targeted therapy, have risen rapidly in recent years. As payors embrace the indication-based paradigm for managing cancer care costs, manufacturers and marketers must adapt their efforts to a more integrated value-based approach.
The global movement toward new pricing methods has dramatically affected how novel cancer therapies are evaluated. The oncology therapeutics industry is in the midst of an ever-changing, inconsistent reimbursement landscape, which is increasing the amount of capital spending from the patient’s side.
Safety concerns regarding severe adverse effects: The therapeutic utility of monoclonal antibody (mAB)-based therapy in clinical oncology, particularly hematological malignancies, is well established. However, infusing these medicines into patients may result in additional medical issues such as serum sickness, and acute anaphylaxis.
Furthermore, mAB-based therapy might produce mild to severe allergies and capillary leak syndrome. It should be highlighted that the negative impacts of mAB-based therapy vary from patient to patient.
On the other hand, patients who receive chimeric antigen receptor (CAR) T-cell therapy for hematological malignancies experience extra adverse effects.
Among these adverse effects include cytokine release syndrome (CRS), high fever, low blood counts, and neurotoxicity. As a result, the risks and adverse effects associated with the use of mAB-based treatments and CAR-T therapies are predicted to limit the adoption of new hematological malignancies medications.
To summarize, there are a few restraints like high adoption costs, reimbursement, and safety concerns regarding severe adverse effects that are considerably impacting the dynamicity of the global hematological malignancies emerging therapeutics market and may reduce the efficiency of the industry.
Do you want to discover more about emerging technologies? BIS Research provides the most recent market insights and analyses. To learn more, please contact us at hello@bisreseach.com.
